Navtemadlin is under clinical development by Kartos Therapeutics and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Navtemadlin’s likelihood of approval (LoA) and phase transition for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) took place on 20 Jul 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 20 Jul 2022 increased Navtemadlin’s LoA and PTSR for Post-Polycythemia Vera Myelofibrosis (PPV-MF).

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Navtemadlin Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Navtemadlin overview

Navtemadlin is under development for the treatment of relapsed or refractory small cell lung cancer, primary myelofibrosis, polycythemia vera, post-polycythemia vera myelofibrosis (PPV-MF), relapsed/refractory diffuse large B-cell lymphoma or relapsed/refractory chronic lymphocytic leukemia, chronic myelocytic leukemia, Merkel cell carcinoma, post-essential thrombocythemia myelofibrosis (Post-ET MF) and relapsed and refractory acute myeloid leukemia, soft tissue sarcoma, liposarcoma, metastatic breast cancer. The drug candidate is administered through oral route as tablet. It acts by targeting murine double minute 2 (Mdm2).

It was also under development for relapsed, refractory multiple myeloma, metastatic cutaneous melanoma, glioblastoma multiforme (GBM) and recurrent glioblastoma multiforme (GBM).

Kartos Therapeutics overview

Kartos Therapeutics is a clinical stage biopharmaceutical company dedicated to the development of novel, targeted therapeutics. Kartos Therapeutics is headquartered in Redwood City, California, the US.

Quick View Navtemadlin LOA Data

Report Segments
  • Innovator
Drug Name
  • Navtemadlin
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: Kartos Therapeutics
  • Originator: Amgen
Highest Development Stage
  • Phase III


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.